These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38861284)

  • 21. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 22. Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries.
    Lo SH; Lawrence C; Martí Y; Café A; Lloyd AJ
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):103-115. PubMed ID: 34897574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.
    Coates E; Wickramasekera N; Barr A; Shackley P; Lee M; Hind D; Probert C; Sebastian S; Totton N; Blackwell S; Bedford H; Dames N; Lobo A
    Health Technol Assess; 2022 Oct; 26(41):1-118. PubMed ID: 36305390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment.
    Livingstone A; Howard K; Menzies AM; Long GV; Stockler MR; Morton RL
    Patient; 2023 Sep; 16(5):497-513. PubMed ID: 37351797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
    van den Wijngaard L; Rodijk IC; van der Veen F; Gooskens-van Erven MH; Koks CA; Verhoeve HR; Mol BW; van Wely M; Mochtar MH
    Hum Reprod; 2015 Feb; 30(2):331-7. PubMed ID: 25432926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The perspective of women with an increased risk of OHSS regarding the safety and burden of IVF: a discrete choice experiment.
    Braam SC; de Bruin JP; Mol BWJ; van Wely M
    Hum Reprod Open; 2020; 2020(2):hoz034. PubMed ID: 32123754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
    Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
    Front Public Health; 2021; 9():653450. PubMed ID: 33842426
    [No Abstract]   [Full Text] [Related]  

  • 29. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
    Stumpf J; Al-Sawaf O
    Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment.
    Wong XY; Lim AQJ; Shen Q; Chia JWK; Chew MH; Tan WS; Wee HL
    Curr Med Res Opin; 2020 Oct; 36(10):1677-1686. PubMed ID: 32609014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment.
    Buchanan J; Wordsworth S; Schuh A
    Patient; 2016 Dec; 9(6):525-536. PubMed ID: 27167075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation.
    Marshall DA; MacDonald KV; Kao D; Bernstein CN; Kaplan GG; Jijon H; Hazlewood G; Panaccione R; Nasser Y; Raman M; Moayyedi P
    Ther Adv Chronic Dis; 2024; 15():20406223241239168. PubMed ID: 38544906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation.
    Saini L; Griffin JD; Pandya BJ; Shah MV; Zhou M; Yang H; Song Y; Marshall DA
    Patient Prefer Adherence; 2023; 17():2805-2819. PubMed ID: 37953977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update in the management of chronic lymphocytic leukemia.
    Maddocks KJ; Lin TS
    J Hematol Oncol; 2009 Jul; 2():29. PubMed ID: 19619273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAPER: patient preferences to inform nonsurgical treatment of chronic low back pain: a discrete-choice experiment.
    Wilson L; Zheng P; Ionova Y; Denham A; Yoo C; Ma Y; Greco CM; Hanmer J; Williams DA; Hassett AL; Scheffler AW; Valone F; Mehling W; Berven S; Lotz J; O'Neill C
    Pain Med; 2023 Aug; 24(8):963-973. PubMed ID: 36975607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient Preferences for Treatment in Relapsed/Refractory Acute Leukemia in the United Kingdom: A Discrete Choice Experiment.
    Mott DJ; Hitch J; Nier S; Pemberton-Whiteley Z; Skedgel C
    Patient Prefer Adherence; 2024; 18():1243-1255. PubMed ID: 38911590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chinese patients' preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment.
    Si L; Tu L; Xie Y; Palmer AJ; Gu Y; Zheng X; Li J; Lv Q; Qi J; Lin Z; Chen M; Gu J; Hiligsmann M
    Arch Osteoporos; 2019 Jul; 14(1):85. PubMed ID: 31367860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
    Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
    Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.